AIM: To investigate the efficacy of different dosage of
polysaccaride sulfate (PSS) in ischemic heart and cerebral disease
patients with
hyperlipidemia. METHODS: One hundred and twenty eight cases of hyperlipidemia were randomly divided into 2 groups, the former (group A, 68 cases) given PSS 300 mg/d, while the later (group B, 60 cases) 600 mg/d. Serum lipid was measured before and 4 wk, 8 wk after the treatment. PSS had to be added to 600 mg/d for another 8 wk of the group A patients whose serum lipid had not be controlled in the ideal level. RESULTS: ① Serum total cholesteral (TC) and low density lipoprotein cholesteral (LDL C) were decreased significantly ( P <0 05) in 2 groups. Serum triglyceride (TG) was decreased and high density lipoprotein cholesterol (HDL C) was increased seperately in group B at the same time. ② The Total efficacy in group B was better than that in group A, including lowering TC, TG, LDL C and raising HDL C. There were much significant statistical differences between them ( P <0 01). PSS dosage in 44 patients of group A had to be added from 300 mg/d to 600 mg/d for ideal serum lipid control, and TC and LDL C were decreased by 75% after another 8 wk. ③ There were no great changes in blood routine, urine routine, liver and renal function before and after the treatment. CONCLUSION: In ischemic heart and cerebral disease patients with hyperlipidemia, the efficacy of PSS in decreasing serum TC, LDL C, and TG is certain, giving PSS 600 mg/d is better in regulating hyperlipidemia. Not only the serum TC and LDL C be lowed, but TG be decreased and HDL C be increased. No serious adverse drug reaction is found in the 2 groups.